Insulin-like growth factor ligands, receptors, and binding proteins in cancer

Journal of Pathology

Volumn 205, Issue 2, 2005, Pages 145-153

  Foulstone, E ^a   Prince, S ^a   Zaccheo, O ^a   Burns, J L ^a   Harper, J ^a   Jacobs, C ^a   Church, D ^a   Hassan, A B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cancer models; Cancer therapy; Insulin like growth factor binding proteins; Insulin like growth factor I; Insulin like growth factor I receptor; Insulin like growth factor II; Insulin like growth factor II receptor

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR;

BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG SENSITIVITY; FUNCTIONAL GENOMICS; GENE MUTATION; HUMAN; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CARRIER PROTEINS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, SOMATOMEDIN; SOMATOMEDINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13644262798     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1712     Document Type: Review

References (76)

1. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
2. Pollack MN, Scherbhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Rev Cancer 2004; 4: 505-518.
3. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24.
4. Hassan AB. Keys to the hidden treasures of the mannose 6-phosphate/insulin-like growth factor 2 receptor. Am J Pathol 2003; 162: 3-6.
5. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Op Pharm 2003; 3: 371-377.
6. Scott CD, Firth SM. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm Metab Res 2004; 36: 261-271.
7. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 149: 367-372.
8. Freeman M, Gurdon JB. Regulatory principles of developmental signaling. Annu Rev Cell Dev Biol 2002; 18: 515-539.
9. Siddle K, Urso B, Niesler CA, et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29: 513-525.
10. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
11. Birkenkamp KU, Coffer PJ. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class 0) subfamily of Forkhead transcription factors. Biochem Soc Trans 2003; 31: 292-297.
12. Accili D, Arden KC. FOXOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117 421-426.
13. Murphy CT, McCarroll SA, Bargmann CI, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 2003; 424: 277-283.
14. Seoane J, Le H-V, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223.
15. Hu MC, Lee DF, Xia W, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225-237.
16. Zeslawski W, Beisel H-G, Kamionka M, et al. The interaction of insulin-like growth factor-I with N-terminal domain of IGFBP-5. EMBO J 2001; 20: 3638-3644.
17. Favelyukis S, Hill JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nature Struct Biol 2001; 8: 1058-1063.
18. Sorensen H, Whittaker L, Hinrichsen J, Groth A, Whittaker J. Mapping of the insulin-like growth factor II binding site of the type I insulin-like growth factor receptor by alanine scanning mutagenesis. FEBS Lett 2004; 565: 19-22.
19. Luo RZ, Beniac DR, Fernandes A, Yip CC, Ottensmeyer FP. Quaternary structure of the insulin-insulin receptor complex. Science 1999; 285: 1077-1080.
20. Lawlor MA, Alessi DR. PKB/Akt; a key mediator of cell proliferation, survival, and insulin responses? J Cell Sci 2001; 114: 2903-2910.
21. Riedel H. Grb10 exceeding the boundaries of a common signaling adapter. Front Biosci 2004; 9: 603-618.
22. Charalambous M, Smith FM, Bennett WR, Crew TE, Mackenzie F, Ward A. Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. Proc Natl Acad Sci U S A 2003; 100: 8292-8297.
23. Denley A, Bonython ER, Booker GW, et al. Structural determinants for high affinity binding of IGF-II to IR-A, the exon 11 minus isoform of the insulin receptor Mol. Endocrinol 2004; 18 2502-2512.
24. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Rev 2002; 23: 824-854.
25. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 2003; 14: 176-181.
26. Wood TL, Rogler LE, Czick ME, Schuller AGP, Pintar JE. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol Endocrinol 2000; 14: 1472-1482.
27. Hoflich A, Nedbal S, Blum WF, et al. Growth inhibition in giant growth hormone transgenic mice by over-expression of insulin-like growth factor binding protein-2. Endocrinology 2001; 142: 1889-1898.
28. Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999; 146: 881-892.
29. Neuenschwander S, Scwartz A, Wood TL, Roberts CT, Henninghausen L. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 1996; 97: 2225-2232.
30. Linnell J, Groeger G, Hassan AB. Real time kinetics of insulin-like growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor: the effects of domain 13 and pH. J Biol Chem 2001; 276: 23 986-23 991.
31. Brown J, Esnouf RM, Jones MA, et al. Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J 2002; 21: 1054-1062.
32. Garmroudi F, Devi G, Slentz DH, Schaffer BS, MacDonald RG. Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding. Mol-Endocrinol 1996; 10: 642-651.
33. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990; 345 78-80.
34. Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 1994; 8: 2953-2963.
35. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. Disruption of imprinting caused by deletion of the H19 gene region in mice [see comments]. Nature 1995; 375: 34-39.
36. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75 59-72.
37. Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2003; 131: 1187-1194.
38. Hassan AB, Howell JA. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 2000; 60: 1070-1076.
39. Lopez T, Hanahan D. Elevated levels of the IGF-I receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumourigenesis. Cancer Cell 2002; 1: 339-353.
40. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000; 275: 28 341-28 344.
41. Christofori G, Naik P, Hanahan D. Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis. Nature Genet 1995; 10: 196-201.
42. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369: 414-418.
43. Haddad R, Held WA. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res 1997; 57: 4615-4623.
44. Hassan AB, Macaulay VM. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 2002; 13 349-356.
45. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryonic fibroblasts. Mol Cell Biol 1994; 14: 3604-3612.
46. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumour antigen is unable to transform mouse embryonic fibroblasts lacking type I insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993; 90: 11 217-11 221.
47. Almeida A, Muleris M, Dutrillaux B, Malloy B. The insulin-like growth factor I receptor is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer 1994; 11: 63-65.
48. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950.
49. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor 1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumours. Cancer Cell 2004; 5 221-230.
50. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725-1729.
51. Hankins GR, De Souza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12: 2003-2009.
52. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2001; 19: 1572-1578.
53. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet 1995; 11: 447-449.
54. Souza RF, Wang S, Thakar M, et al. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal cancer cells. Oncogene 1999; 18 4063-4068.
55. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF12 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-1755.
56. Jirtle RL. IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer. Gastroenterology 2004; 126 1190-1201.
57. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353.
58. Wu Y, Yakar S, Zhao L, Henninghausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62: 1030-1035.
59. Slattery ML, Samowitz W, Curtin K, et al. Associations among IRS1, IRS2, IGF1 and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1206-1214.
60. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-I receptor. Cancer Cell 2004; 5: 201-202.
61. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003; 22: 6589-6597.
62. Min Y, Adachi Y, Yamamoto H, et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003; 63: 6432-6441.
63. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumour growth in vivo. Cancer Res 2003; 63: 8912-8921.
64. Lamm GM, Christofori G. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res 1998; 58: 801-807.
65. Wendel HG, de Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
66. Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J Biol Chem 1988; 263(13): 6233-6239.
67. Clemmons DR, Dehoff ML, Busby WH, et al. Competition for binding to insulin-like growth factor (IGF) binding protein-2,3,4, and 5 by the IGFs and IGF analogs. Endocrinology 1992; 131 2): 890-895.
68. Francis GL, Aplin SE, Milner SJ, et al. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J 1993; 293(Pt 3): 713-719.
69. Bach LA, Hsieh S, Sakano K, et al. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem 1993; 268(13): 9246-9254.
70. Cascieri MA, Chicchi GG, Applebaum J, et al. Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor. J Biol Chem 1988; 27(9): 3229-3233.
71. Bayne ML, Applebaum J, Chicchi GG, et al. The roles of tyrosines 24,31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. J Biol Chem 1990; 265(26): 15 648-15 652.
72. Forbes BE, Hartfield PJ, McNeil KA, et al. Characteristics of binding of insulin-like growth factor (IGF)-I and (IGF-II) analogues to the type 1 IGF receptor determined by BIAcore analysis. Eur J Biochem 2002; 269(3): 961-968.
73. Sakano K, Enjoh T, Numata F, et al. The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 1991; 266(31): 20 626-20 635.
74. Forbes BE, McNeil KA, Scott CD, et al. Contribution of residues A54 and L55 of the human insulin-like growth factor-II (IGF-II) A domain to Type 2 IGF receptor binding specificity. Growth Factors 2001; 19(3): 163-173.
75. Cascieri MA, Chicchi GG, Applebaum J, et al. Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors. J Biol Chem 1989; 264(4): 2199-2202.
76. Kristensen C, Kjeldsen T, Wiberg FC, et al. Alanine scanning mutagenesis of insulin. J Biol Chem 1997; 272(20): 12 978-12 983.